touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D.
Question:
- What are the unmet needs in diagnosis and treatment of hepatitis? (0:20)
Disclosures: Dr Thomas Berg has received grant/research support from Abbvie, Gilead, and MSD/Merck; and is on the advisory board for Abbvie, Gilead, GSK, Janssen, and MSD/Merck; and is also a speaker’s bureau participant with Abbvie, Gilead, and MSD/Merck.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
